Namenda (Alzheimer's Disease) - Forecast and Market Analysis to 2022 - PR Newswire (press release)

LONDON, Dec. 26, 2013 /PRNewswire/ -- Reportbuyer.com just published a new market research report:

Namenda (Alzheimer's Disease) - Forecast and Market Analysis to 2022 ^[1]

Namenda (Alzheimer's Disease) - Forecast and Market Analysis to 2022

Summary

GlobalData has released its new PharmaPoint Drug Evaluation report, "Namenda (Alzheimer's Disease) - Forecast and Market Analysis to 2022". There are no long-term effective therapies for Alzheimer's Disease (AD), so this remains at the top of the list for unmet needs. While physicians agree that symptomatic therapies are relatively safe and effective, these therapies are still lacking because of they cannot maintain their effects and lack mechanisms that alter the course of the disease.

Namenda (memantine hydrochloride) is a first-in-class medication for AD with a unique MOA compared with the currently available drugs. It is an orally-active NMDA receptor antagonist and was the first, and at the time, the only, medication approved for the treatment of moderate to severe dementia of the Alzheimer's type.

Scope

- Overview of AD, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.

- Detailed information on Namenda including product description, safety and efficacy profiles as well as a SWOT analysis.

- Sales forecast for Namenda for the top nine countries from 2012 to 2022.

- Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan, China and India.

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return

- Stay ahead of the competition by understanding the changing competitive landscape for AD

- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential

- Make more informed business decisions from insightful and in-depth analysis of Namenda performance

- Obtain sales forecast for Namenda from 2012-2022 in top nine countries (the US, France, Germany, Italy, Spain, the UK, Japan, China and India)

Table of Contents

1 Table of Contents 5

1.1 List of Tables 7

1.2 List of Figures 7

2 Introduction 8

2.1 Catalyst 8

2.2 Related Reports 9

3 Disease Overview 11

3.1 Etiology and Pathophysiology 12

3.1.1 Etiology 12

3.1.2 Pathophysiology 15

3.2 Symptoms 27

4 Disease Management 29

4.1 Diagnosis 29

4.1.1 Probable Alzheimer's Disease Dementia 30

4.1.2 Possible AD Dementia 31

4.1.3 Probable AD Dementia with Evidence of AD Pathophysiological Process 31

4.1.4 Possible Alzheimer's Dementia with Evidence of the Alzheimer's Disease Pathophysiological Process 32

4.1.5 Preclinical AD 32

4.1.6 Mild Cognitive Impairment 33

4.2 Treatment Overview 35

5 Competitive Assessment 38

5.1 Overview 38

5.2 Strategic Competitor Assessment 38

6 Namenda (memantine hydrochloride) 41

6.1 Overview 41

6.2 Efficacy 42

6.3 Safety 43

6.4 SWOT Analysis 44

6.5 Forecast 44

7 Appendix 46

7.1 Bibliography 46

7.2 Abbreviations 50

7.3 Methodology 53

7.4 Forecasting Methodology 53

7.4.1 Diagnosed AD patients 54

7.4.2 Percent Drug-treated Patients 55

7.4.3 General Pricing Assumptions 55

7.4.4 Individual Drug Assumptions 57

7.4.5 Generic Erosion 57

7.5 Physicians and Specialists Included in this Study 58

7.6 About the Authors 59

7.6.1 Author 59

7.6.2 Global Head of Healthcare 60

7.7 About GlobalData 61

7.8 Disclaimer 61

List of Tables

Table 1: Symptoms of AD 28

Table 2: Guidelines for the Treatment of AD 35

Table 3: Most Prescribed Drugs for AD by Class in the Global Markets, 2012 36

Table 4: Leading Branded Treatments for AD, 2013 39

Table 5: Product Profile– Namenda 42

Table 6: Namenda SWOT Analysis, 2013 44

Table 7: Global Sales Forecasts ($m) for Namenda, 2012–2022 45

List of Figures

Figure 1: Atrophy of the Brain in AD 17

Figure 2: Key Pathological Features in AD Versus a Healthy Neuron 19

Figure 3: Non-Amyloidogenic Metabolism of APP 21

Figure 4: Amyloidogenic Metabolism of APP 22

Figure 5: Neurofibrillary Tangles 24

Figure 6: Oxidative Damage Due to Free Radicals 26

Figure 7: Strategic Competitor Assessment of the Marketed Products in AD, 2013 40

Read the full report:

Namenda (Alzheimer's Disease) - Forecast and Market Analysis to 2022

http://www.reportbuyer.com/pharma_healthcare/diseases/namenda_alzheimers_disease_forecast_market_analysis_2022.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology ^[2] ^[3]

For more information:

Sarah Smith

Research Advisor at Reportbuyer.com

Email: query@reportbuyer.com

Tel: +44 208 816 85 48

Website: www.reportbuyer.com ^[4] ^[5]